Digital Therapeutics · Chronic Pain

Turning down
the volume
on pain.

A clinically-validated VR therapy platform that delivers real pain relief to the millions who can't reach the clinic.

Series A
Confidential · 2025
The Access Gap

Chronic pain is everywhere.
Effective, safe treatment isn't.

72%
of the 51M U.S. adults living with chronic pain never receive specialized, non-drug care — blocked by cost, distance, and 6-month waitlists.
$635B
annual U.S. cost of chronic pain — more than cancer & diabetes combined
1 in 4
opioid prescriptions still written for pain we can now treat digitally
The Problem02 / 11
Why Now

Three curves just crossed — and the window is open.

10×
Hardware finally cheap
Standalone VR headsets dropped below $300 and shipped to 30M+ homes — the delivery device is already in the living room.
2
FDA cleared the path
Prescription digital therapeutics now have a defined regulatory & reimbursement pathway, with the first VR pain device cleared in 2021.
$0
Payers want alternatives
Post-opioid, insurers are actively funding non-drug pain programs. CPT codes for digital therapy went live in 2023.
Why Now03 / 11
The Platform

Lumen delivers
the pain clinic
through a headset.

A prescribed, guided VR program that retrains the brain's pain response — 20 minutes a day, at home, no addiction risk.

01
Neuroscience-backed protocols
Immersive modules built on cognitive-behavioral therapy, biofeedback, and pain-reprocessing science.
02
Adaptive & measured
Real-time biometric feedback tunes each session and streams outcome data to clinicians.
03
Prescribed & reimbursable
Delivered as an FDA-pathway digital therapeutic with an established billing code.
The Solution04 / 11
Clinical Rigor

The science holds up
in randomized trials.

−48%Lumen VR
therapy
−26%Standard
digital CBT
−9%Sham /
control
Mean reduction in pain-intensity score · 12-week endpoint
−48%
Average reduction in patient-reported pain across our multi-site randomized controlled trial — sustained at 12 weeks.
3
peer-reviewed studies
412
enrolled patients
87%
program adherence
Validation05 / 11
Traction

Prescribed, reimbursed,
and growing fast.

14
clinics & pain centers actively prescribing Lumen
6,200+
patients treated across pilot deployments
$2.1M
ARR run-rate from provider & payer contracts
3
signed payer reimbursement agreements
Quarterly recurring revenue
Q1'24Q2Q3Q4Q1'25Q2'25
Deployment partners
Stanford Pain Medicine · Mayo Clinic pilot
Cleveland Clinic · UnitedHealth (payer LOI)
Traction06 / 11
Market

A pain market
ready to go digital.

TAM $635B
SAM $48B
$4.6B
SOM · 2030
$635BTotal pain economy. Direct spend + lost productivity in the U.S. alone.
$48BServiceable market. Non-drug chronic pain treatment addressable via digital therapy.
$4.6BOur beachhead by 2030. Prescribed VR pain therapy, growing 38% CAGR.
Market07 / 11
Team

Clinicians and builders
who've shipped this before.

Backed by advisors from
Stanford Pain Medicine, the FDA Digital Health office, and two DTx companies acquired for $1B+.
Dr. Elena Voss
CEO & Co-Founder
Pain physician, former Stanford. Led two DTx clinical programs to FDA clearance.
Marcus Reyes
CTO & Co-Founder
Ex-Oculus principal engineer. Built the real-time biometric VR stack.
Dr. Priya Anand
Chief Science Officer
Neuroscientist, 40+ publications on pain reprocessing therapy.
James Okonkwo
Head of Commercial
Scaled payer contracts at a leading digital therapeutics firm.
Team08 / 11
The Ask
$12M
Series A to reach FDA clearance and national payer coverage.
Use of Funds
Pivotal FDA trial40%
Product & platform25%
Commercial & payer20%
Team & operations15%
Trial Product Commercial Team Runway to FDA clearance · 24 months
The Ask09 / 11
What $12M Buys

The 24-month path
to a category leader.

Q2'26
Pivotal trial readout
Complete the 600-patient FDA registrational study and submit for De Novo clearance.
Q4'26
FDA clearance + coverage
Secure marketing authorization and expand from 3 to 10 national payer contracts.
'27
$20M ARR at Series B
100+ prescribing centers, 60K patients treated, and a clear path to profitability.
Milestones10 / 11
Let's Build It

Relief that reaches
everyone.

Dr. Elena Voss · Founder & CEO
[email protected]
lumenhealth.com

Series A · $12M · 2025